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Introduction
Escherichia coli (E. coli) remains an important cause
of urinary tract infections (UTIs). UTI by extended-
spectrum â-lactamase (ESBL) producing strains of E.
coli is difficult to treat. Concomitant resistance to
other non â-lactam antibiotics like aminoglycosides
and fluoroquinolones has further complicated the
situation and left very limited treatment options,
especially per oral regimes.1 Mecillinam is an oral
amidinopenicillin which acts by binding with penicillin
binding protein-2 (PBP-2). It is relatively stable to â-
lactamase enzymes and reaches very high concentration
in urine.2 Thus mecillinam is proven to be a suitable
antimicrobial agent against ESBL producing
uropathogens like E. coli and Klebsiella spp. But,
chromosomal mutation and few beta-lactamase induced
mechanism results in mecillinam resistance in clinical
isolates.3-5 Though mecillinam resistance has been
reported from various part of the world it is less
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Abstract
Mecillinam is one of the very few oral antibacterial agents used against extended spectrum β-
lactamase (ESBL) producing Escherichia coli (E. coli) causing urinary tract infection (UTI)). It is
reported that, resistance to mecillinam can be reversed to some extent by adding beta lactamase
inhibitor like clavulanic acid. The present study was aimed to determine in-vitro activity of
mecillinam and mecillinam-clavulanic acid combination on the susceptibility of ESBL producing
and non-ESBL producing E. coli. Total 124 E. coli (78 ESBL positive and 46 ESBL negative)
isolates from urine samples of patients with UTI were included in the study. Organisms were
isolated from patients attending BIRDEM General Hospital from July 2012 to December 2012.
ESBL production was tested by double disc synergy test. Minimum inhibitory concentration (MIC)
of mecillinam and clavulanic acid against E. coli was determined by agar dilution method. Of the
total E. coli isolates, 62.9% was ESBL positive and 37.1% was negative for ESBL. Out of ESBL
positive isolates, 75.6% was sensitive to mecillinam while ESBL negative isolates showed the
sensitivity as 67.4%. The sensitivity to mecillinam of ESBL positive and negative isolates increased
to 85.9% and 86.9% respectively by addition of clavulanic acid with mecillinam. The MIC values
of intermediate and resistant isolates converted to sensitive MIC range after addition of clavulanic
acid with mecillinam. Conversion of resistance of ESBL producing isolates by adding clavulanic
acid was also evident by the reduction of MIC50 and MIC90 from 4µg/ml to ≤1 µg/ml and from 128 µg/
ml to 64 µg/ml respectively. Similar trend of reduction of MICs was also observed in non-ESBLs.
In conclusion, both ESBL positive and negative E. coli demonstrated considerable sensitivity to mecillinam
and the sensitivity increased significantly (p<0.05) by adding clavulanic acid with mecillinam.
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pronounced than other beta-lactams.6,7 In vitro studies
have shown that mecillinam resistance conferred by
higher inoculum can be reversed by addition of beta-
lactamase inhibitors like clavulanic acid.8 Clavulanic
acid is a beta lactam compound that has weak intrinsic
antibacterial activity. When used in combination with
other â-lactam drugs it exerts synergistic effect by
inhibiting beta lactamase enzymes.9,10
The aim of the present study was to assess in vitro
activity of mecillinam alone and in combination with
clavulanic acid against ESBL producing and ESBL
non-producing uropathogenic E. coli.
Material and Method
Bacterial strains
Total 124 E. coli strains isolated from urine samples
were included in the study. Urine was collected from
both indoor and outdoor patients attending BIRDEM
General Hospital during the period of July 2012 to
December 2012. Isolation and identification of the
species was done according to standard laboratory
methods.11
Detection of ESBL
Double disc synergy test was employed to detect ESBL
production.12 Bacterial suspension of 0.5 McFarland
standard was plated in Muller-Hinton agar with
Amoxycillin-clavulanic acid (30 µg) disc in between
and 20 mm apart from Ceftazidime (30 µg) and
Ceftriaxone (30 µg) discs. Expansion of the zone of
inhibition around Ceftriaxone and/or ceftazidime disc
towards the amoxycillin-clavulanic acid disc was
considered ESBL production.
Determination of MIC
Antimicrobial susceptibility of E. coli strains was
tested by agar dilution method as described in CLSI
guideline.11 Minimum inhibitory concentrations (MICs)
of mecillinam was determined in Muller-Hinton agar
plate containing two fold (Log2) serial dilutions of
mecillinam (from 1024 µg/ml to 1 µg/ml) using
standard inoculum of 1x104 cfu/spot. MICs of
mecillinam were also determined in presence of
clavulanic acid at a concentration of 0.04µg/ml in each
plate. MIC values (µg/ml) were interpreted as:
sensitive: ≤ 8, Intermediate: 16 and Resistant: ≥ 32.
E. coli ATCC 25922 was used as negative control and
a mecillinam resistant E. coli isolates having MIC of
>1024 µg/ml (pre-determined) was used as positive
control. Pivmecillinam and potassium clavulanate were
obtained from General Pharmaceuticals Ltd.
Bangladesh, and Incepta Pharmaceuticals Ltd.
Bangladesh.
Results
Table-1 shows the susceptibility pattern of ESBL
positive and negative E. coli isolates to mecillinam
and mecillinam+clavulanic acid according to MIC
values. Mecillinam sensitivity was demonstrated in
75.6% ESBL positive and 67.4% ESBL negative
isolates which was augmented to 85.9% and 86.9%
respectively after addition of clavulanic acid. In ESBL
positive and negative strains 5.2% and 8.7% isolates
were intermediately sensitive to mecillinam, whereas
none of the isolates were intermediate sensitive to
mecillinam+ clavulanic acid combination. Resistance
to mecillinam was found in 19.2% and 23.9% ESBL
positive and negative isolates that were reduced to
Table-1: Susceptibility pattern of ESBL positive and ESBL negative E. coli to mecillinam and mecillinam+
clavulanic acid according to MIC values (N=124)
Susceptibility MIC No (%) of isolates inhibited
pattern (µg/ml)       ESBL Positive (n=78)     ESBL Negative (n=46)
MEC MEC+CLA MEC MEC+CLA
Sensitive ≤1-8 59 (75.6%) 67 (85.9%) 31 (67.4%) 40(86.9%)
Intermediate 16 04 (5.2%) 0 (0.0%) 04 (8.7%) 0 (0.0%)
Resistant ≥32 15 (19.2%) 11 (14.1%) 11 (23.9%) 6 (13.1%)
Note: MEC=mecillinam, CLA=clavulanic acid
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14.1% and 13.1% after adding clavulanic acid with
mecillinam respectively.
All the isolates having 16 µg/ml and 32 µg/ml MIC
of mecillinam converted to sensitive after addition
of clavulanic acid. Out of 5 isolates having MIC of
64µg/ml, 2 (40%) were converted to sensitive. But
the isolates having MIC of ≥ 128 demonstrated no
change in susceptibility. Total 55.9% intermediately
sensitive and resistant E. coli became sensitive to
mecillinam by adding clavulanic acid (Table-2).
The MIC of mecillinam against ESBL producing E.
coli ranged from ≤1-≥1024 µg/ml. MIC50 and MIC90
were 4 and 128 µg/ml respectively. After adding
clavulanic acid with mecillinam MIC50 and MIC90
reduced to ≤1 µg and 64 µg/ml respectively. In non-
ESBL producing E. coli isolates MIC50 and MIC90
were 4 and 64 µg/ml respectively with mecillinam
and ≤1and 32 with mecillinam+clavulanic acid
(Table-3).
Discussion
ESBL producing E. coli is isolated in very high
frequency in nosocomial as well as community acquired
urinary tract infections.8,13-15 In the present study, about
69% inpatient and 57% outpatient E. coli isolates were
found ESBL producer. This proportion of ESBL
isolation is similar to those described in several studies
in home and abroad.8,13,14 A considerable numbers of
isolates irrespective of ESBL production showed
sensitivity to mecillinam. The high susceptibility rate
of ESBL producing E. coli to mecillinam as
determined by MIC method in this study is comparable
to the findings of others who found 94% and 85%
sensitivity respectively.13,14 But in the context of
Bangladesh, mecillinam sensitivity of E. coli was
reported as 43-67% in 2009.14,15 This divergence may
be due to the fact that, in those studies uropathogenic
E. coli irrespective of ESBL production was considered
and disc diffusion method was used to determine the
sensitivity instead of MIC method.
The present study also demonstrated a significant
proportion of E. coli (27.4%) was mecillinam.
Interestingly, we have observed higher rate of
resistance in ESBL negative isolates. Arguably, ESBL
positive strains should exhibit higher resistance than
negative strains. This discrepancy could be due to small
number of samples. However, though the percentage
of resistance was more in ESBL negative isolates but
the level of resistance was more pronounced in ESBL
positive isolates as shown by the MIC50 and MIC90
values.
Mecillinam is one of the very few oral drug used in
treating community acquired urinary tract infection.
According to in-vitro findings, it is stable against beta
lactamase enzymes produced by gram negative as well
as gram positive bacteria. Extensive use of mecillinam
because of its effectiveness in UTI has exerted
selective pressure resulting in chromosomal mutation
of the drug target and emergence of resistance.
Further, few beta lactamases like type IIIa and IVc
have activity against mecillinam causing hydrolysis
of the agent.10 These factors together results in
mecillinam resistance in clinical practice. Addition
of any compound that has inhibitory effect on these
enzymes may improve the antibacterial activity of
mecillinam. In this ground, activity of mecillinam in
combination with a beta lactamase inhibitor, clavulanic
acid, was also evaluated in the study. Using the agar
Table-2: Change of susceptibility in relation to MIC
values of intermediate sensitive and resistant isolates
after adding clavulanic acid
MIC Intermediate N Isolates converted
mecillinam sensitive & resistant sensitive to MEC
µg/ml isolates to MEC adding CLA
N N (%)
16 8 8 (100%)
32 9 9 (100%)
64 5 2 (40%)
≥128 12 0 (0%)
Total 34 19 (55.9%)
Note: MEC=mecillinam, CLA=clavulanic acid
Table-3: Change of MIC50 and MIC90 values of ESBL
producing and non-ESBL producing E. coli isolates by
addition of clavulinic acid with mecillinam
E. coli   Compound MIC (µg/ml)
isolates MIC50 MIC90 Range
ESBL MEC 4 128 ≤1– ≥1024
producer MEC+CLA ≤1 64 ≤1– ≥1024
Non-ESBL MEC 4 64 ≤1– ≥1024
producer MEC+CLA ≤1 32 ≤1– 512
Note: MEC=mecillinam, CLA=clavulanic acid
Ibrahim Med. Coll. J. 2014; 8(2): 1-559 Shadia K  et al.
dilution method with standard inoculum of 1x104 cfu/
spot, there was a marked decrease in the MIC of
mecillinam when combined with clavulanate. As a
result, sensitivity of ESBLs producing E. coli improved
from 75.6% to 85.9% and for non-ESBLs producers
from 67.4% to 86.9%. The MICs of individual isolates
markedly reduced after adding clavulonic acid, but
overall range of MICs was not changed (ranging from
≤1 - ≥1024). Because MICs of some isolates were out
of the test range it was not possible to determine
whether there was a significant (≥8 fold) decrease in
MIC or not. The lowest value of MIC in our assay
was 1 µg/ml; so in those isolates where MIC reduced
beyond the concentration of 1 µg/ml could not be
determined. Similar things happened in some highly
resistant isolates having the MIC of >1024 µg/ml
which was the highest MIC value tested. But the
additional inhibitory effect of clavulanic acid could be
predicted from the reduction of MIC50 and MIC90 of
mecillinam after adding clavulonic acid (Table-3).
Using the standard inoculum 1x104 cfu/spot, MIC50 of
mecillinam was reduced from 4 µg/ml to ≤1 µg/ml
and MIC90 from 128 µg/ml to 64 µg/ml. These findings
were in accordance with previous studies.8,17 In the
present study similar trend of reduction of MICs was
also observed among ESBL negative E. coli. The
observed synergistic effect of mecillinam-clavulanic
acid combination on ESBL negative isolates could be
due to the presence of other broad spectrum â-
lactamases which were inhibitable by clavulanic acid
or due to the primary affinity of clavulanic acid for
PBP-2 of E. coli like mecillinam.18,9 Altogether, by
adding clavulonic acid with mecillinam about 56% of
resistant isolates became sensitive which were resistant
or intermediately sensitive with mecillinam alone
(Table-2). In the present study, we have further
observed that all intermediate and resistant isolates
having MIC of 16 µg/ml and 32 µg/ml became sensitive
(MIC ≤1-8) when clavulanic acid was added with
mecillinam. But, only 40% isolates having MIC of 64
µg/ml reverted to sensitive range and none of the
isolates having MIC ≥128 µg/ml became sensitive by
adding clavulanic acid. It suggests that there is chance
of treatment response with mecillinam-clavulanic acid
combination in infection with resistant E. coli having
such range of MICs. However, this combination may
not be useful in severe infection by ESBL producers
due to the inoculum effect of the offending organism
on the drugs.7,8,19
The results of our study suggest that clinical trial should
be done to confirm the usefulness of the mecillinam-
clavulanic acid combination therapy in UTI with
intermediate and resistant strains of E. coli having
such range of MICs.
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